These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37019064)

  • 41. Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan.
    Jirawattanapisal T; Kingkaew P; Lee TJ; Yang MC
    Value Health; 2009; 12 Suppl 3():S4-11. PubMed ID: 20586980
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Value of Medicines: A Crucial but Vague Concept.
    Antoñanzas F; Terkola R; Postma M
    Pharmacoeconomics; 2016 Dec; 34(12):1227-1239. PubMed ID: 27444306
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of Health Technology Assessment in Drug Policies: Korea.
    Bae EY
    Value Health Reg Issues; 2019 May; 18():24-29. PubMed ID: 30419447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Eight-year experience of using HTA in drug reimbursement: South Korea.
    Bae EY; Hong JM; Kwon HY; Jang S; Lee HJ; Bae S; Yang BM
    Health Policy; 2016 Jun; 120(6):612-20. PubMed ID: 27086557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion.
    Detiček A; Janzic A; Locatelli I; Kos M
    BMC Health Serv Res; 2018 Jun; 18(1):496. PubMed ID: 29945634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Choosing Wisely: The Korean Perspective and Launch of the 'Right Decision in Cancer Care' Initiative.
    Kim JY; Lee KE; Kim K; Lee MA; Yoon WS; Han DS; Ahn SG; Kang JH
    Cancer Res Treat; 2020 Jul; 52(3):655-660. PubMed ID: 32599973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eliciting preferences for medical devices in South Korea: A discrete choice experiment.
    Lee HJ; Bae EY
    Health Policy; 2017 Mar; 121(3):243-249. PubMed ID: 28117075
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does drug price-regulation affect healthcare expenditures?
    Ben-Aharon O; Shavit O; Magnezi R
    Eur J Health Econ; 2017 Sep; 18(7):859-867. PubMed ID: 27696009
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Health Expenditure Growth under Single-Payer Systems: Comparing South Korea and Taiwan.
    Cheng SH; Jin HH; Yang BM; Blank RH
    Value Health Reg Issues; 2018 May; 15():149-154. PubMed ID: 29730247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Innovative Medical Technology, Health Technology Assessment, and Health Policy: The Case of Remote Patient Monitoring of Cardiac Implantable Electronic Devices in South Korea.
    Lee SS; Salole E
    Telemed J E Health; 2017 Jan; 23(1):25-29. PubMed ID: 27285669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Value-based approaches to healthcare systems and pharmacoeconomics requirements in Asia: South Korea, Taiwan, Thailand and Japan.
    Kamae I
    Pharmacoeconomics; 2010; 28(10):831-8. PubMed ID: 20831290
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of catastrophic out-of-pocket medical expenditure among older adults in the United States and South Korea: what affects the apparent difference?
    Kim N; Jacobson M
    BMC Health Serv Res; 2022 Sep; 22(1):1202. PubMed ID: 36163016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. National reimbursement listing determinants of new cancer drugs: a retrospective analysis of 58 cancer treatment appraisals in 2007-2016 in South Korea.
    Kim ES; Kim JA; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):401-409. PubMed ID: 28010146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hospital Investment Decisions in Healthcare 4.0 Technologies: Scoping Review and Framework for Exploring Challenges, Trends, and Research Directions.
    Vassolo RS; Mac Cawley AF; Tortorella GL; Fogliatto FS; Tlapa D; Narayanamurthy G
    J Med Internet Res; 2021 Aug; 23(8):e27571. PubMed ID: 34435967
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Forecasting the future reimbursement system of Korean National Health Insurance: a contemplation focusing on global budget and Neo-KDRG-based payment systems.
    Kim YK
    J Korean Med Sci; 2012 May; 27 Suppl(Suppl):S25-32. PubMed ID: 22661867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India.
    Dabak SV; Pilasant S; Mehndiratta A; Downey LE; Cluzeau F; Chalkidou K; Luz ACG; Youngkong S; Teerawattananon Y
    Health Res Policy Syst; 2018 Nov; 16(1):115. PubMed ID: 30486827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Health Technology Assessment for Cardiovascular Digital Health Technologies and Artificial Intelligence: Why Is It Different?
    Vervoort D; Tam DY; Wijeysundera HC
    Can J Cardiol; 2022 Feb; 38(2):259-266. PubMed ID: 34461229
    [TBL] [Abstract][Full Text] [Related]  

  • 58. "Sometimes I don't have a pulse … and I'm still alive!" Interviews with healthcare professionals to explore their experiences of and views on population-based digital health technologies.
    Tomasella F; Morgan HM
    Digit Health; 2021; 7():20552076211018366. PubMed ID: 34104464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic scoping review of digital health technologies during COVID-19: a new normal in primary health care delivery.
    Ndayishimiye C; Lopes H; Middleton J
    Health Technol (Berl); 2023; 13(2):273-284. PubMed ID: 36628261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?
    Edlin R; Hall P; Wallner K; McCabe C
    Value Health; 2014 Jun; 17(4):438-44. PubMed ID: 24969005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.